Mr Billy Ray Poe, RPH in New Market, AL - Pharmacist

Mr Billy Ray Poe, RPH is a Pharmacist based in New Market, Alabama. Mr Billy Ray Poe is licensed to practice in Alabama (license number 9234) and his current practice location is 5324 Winchester Rd, New Market, Alabama. He can be reached at his office (for appointments etc.) via phone at (256) 379-4670.

NPI number for Mr Billy Ray Poe is 1942356050 and his current mailing address is 5324 Winchester Rd, New Market, Alabama. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1942356050.

Contact Information

	Mr Billy Ray Poe, RPH
	5324 Winchester Rd, New Market, AL 35761-7430
	(256) 379-4670
	(256) 379-4680

Healthcare Provider's Profile

Full Name	Mr Billy Ray Poe
Gender	Male
Speciality	Pharmacist
Location	5324 Winchester Rd, New Market, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1942356050
Provider Enumeration Date: 01/25/2007
Last Update Date: 07/08/2007

Medical Identifiers

Medical identifiers for Mr Billy Ray Poe such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1942356050	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	9234 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Billy Ray Poe is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Billy Ray Poe, RPH 5324 Winchester Rd, New Market, AL 35761-7430 Ph: (256) 379-4670	Mr Billy Ray Poe, RPH 5324 Winchester Rd, New Market, AL 35761-7430 Ph: (256) 379-4670

News Archive

Genta commences new tesetaxel Phase 2 clinical trial in advanced bladder cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2 clinical trial of tesetaxel in patients with advanced bladder cancer. Tesetaxel is the leading oral taxane in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY, the Kimmel Cancer Center at Jefferson University, Philadelphia, PA, and at least one site in the EU.

Psychological toll of COVID-19 pandemic linked with anti-systemic attitudes and political violence

The COVID-19 pandemic is the most severe global health crisis of the 21st century. While media reports and policy directives tend to focus on the health and economic aspects of the pandemic, new research suggests that the pandemic is also destabilizing the fundamental relationship between citizens and the state.

FSU researchers link prenatal nicotine exposure to future ADHD

Prenatal exposure to nicotine could manifest as attention deficit hyperactivity disorder in children born a generation later, according to a new study by Florida State University College of Medicine researchers.

Results raise concern about menthols being marketed as a 'starter product' for kids

A new study on mentholated cigarette use in the U.S. finds an increase in menthol cigarette smoking among young adults and concludes that efforts to reduce smoking likely are being thwarted by the sale and marketing of mentholated cigarettes, including emerging varieties of established youth brands.

Mr Billy Ray Poe, RPH - Pharmacist in New Market, AL